MHRA (UK)
OTHER
Continuous renal replacement therapy (CRRT): Consider delayed administration of concurrent echinocandins, such as caspofungin, to reduce the risk of adsorption onto new polyacrylonitrile (PAN)-based filter membranes DSI/2026/014
Published: 10/13/2026Detected: 10/13/2026
Summary preview
Recommends considering delayed administration of concurrent echinocandins (e.g., caspofungin) during CRRT using new polyacrylonitrile (PAN)-based filter membranes to reduce drug adsorption onto the filter.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountinfectious_disease
clinical
safety
labeling
quality
#MHRA
#CRRT
#caspofungin
#echinocandins
#polyacrylonitrile
Official Source Document Source Verified
Access the original document directly from MHRA.
More from MHRA (UK)
- Class 2 Medicines Recall: Norgine Pharmaceuticals Limited, Pedmarqsi 80 mg/mL solution for infusion, EL(26)A/4210/12/2026
- Nova Biomedical StatStrip ketone test strips: risk of disruption to blood ketone testing due to quality-control failures and supply interruption DSI/2026/01310/9/2026
- Field Safety Notices for October 202610/9/2026
- Field Safety Notices: 8 -12 June 202610/9/2026
- Field Safety Notices: 28 September 2026 to 2 October 202610/9/2026